Table 3. Changes in Body Composition During Neoadjuvant Treatment.
| Outcome | No Resection (n = 57) | Resection (n = 136) | P Value |
|---|---|---|---|
| TAT, median (IQR), cm2 | |||
| Pretreatment | 251.0 (165.6 to 392.0) | 301.0 (183.4 to 414.0) | .30 |
| Posttreatment | 244.9 (128.2 to 331.2) | 255.0 (144.0 to 370.2) | .30 |
| Δ TAT | −25.4 (−92.8 to 32.0) | −44.9 (−109.5 to 30.0) | .56 |
| VAT, median (IQR), cm2 | |||
| Pretreatment | 91.8 (50.0 to 168.3) | 123.3 (70.0 to 192.0) | .18 |
| Posttreatment | 67.7 (33.5 to 146.4) | 100.0 (53.0 to 149.0) | .08 |
| Δ VAT | −9.47 (−53.0 to 9.0) | −14.7 (−52.6 to 11.35) | .73 |
| SM, median (IQR), cm2 | |||
| Pretreatment | 126.0 (104.3 to 160.0) | 119.7 (99.0 to 138.6) | .14 |
| Posttreatment | 113.7 (93.2 to 150.0) | 129.0 (106.8 to 153.2) | .06 |
| Δ SM | −2.5 (−16.0 to 3.3) | 7.2 (−2.3 to 19.8) | <.001 |
| TAMA, median (IQR), cm2/m2 | |||
| Pretreatment | 44.4 (37.9 to 52.2) | 42.1 36.4 to 47.7) | .11 |
| Posttreatment | 42.0 (35.8 to 48.8) | 45.1 (40.3 to 50.8) | .049 |
| Δ TAMA | −1.23 (−5.84 to 1.18) | 2.32 (1.25 to 6.72) | <.001 |
| Sarcopenia, No. (%) | |||
| Pretreatment | 21 (36.8) | 63 (46.3) | .27 |
| Posttreatment | 30 (52.8) | 50 (36.8) | .054 |
| Sarcopenic obesity, No. (%) | |||
| Pretreatment | 5 (8.8) | 21 (15.4) | .26 |
| Posttreatment | 8 (14.0) | 17 (12.5) | .82 |
| Tumor size, mean (SD), mm | |||
| Pre-NT | 34.5 (14.2) | 32.1 (12.4) | .38 |
| Post-NT | 31.7 (21.2) | 23.3 (13.3) | <.001 |
Abbreviations: IQR, interquartile range; NT, neoadjuvant treatment; SM, skeletal muscle; TAMA, total abdominal muscle area; TAT, total adipose tissue area; VAT, visceral adipose tissue.